Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics Apr 12, 2023 https://ir.arrowheadpharma.com/news-releases/...ine-rnai-therapeutics - Event to include presentations on cardiometabolic, pulmonary, and newly announced central nervous system pipeline programs
PASADENA, Calif.--(BUSINESS WIRE)--Apr. 12, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m. ET in New York City to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiMTM) platform to a total of 20 clinical stage or marketed products in the year 2025.
Arrowhead also announced that company has expanded its TRiMTM platform to include an optimized intrathecal administration for central nervous system (CNS) delivery with good distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform, ARO-SOD1, is on track for a clinical trial application (CTA) filing in the third quarter of 2023 to begin clinical studies.
ARO-SOD1 is designed to reduce expression of superoxide dismutase 1 (SOD1) in the CNS as a potential treatment for patients with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations. ARO-SOD1 was highly active against its target with a long duration of effect in multiple preclinical models suggesting that it may be administered quarterly or less frequently. In preclinical studies, ARO-SOD1 achieved 95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than 80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates.
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
Tue, April 18, 2023 https://finance.yahoo.com/news/...-webcast-fiscal-2023-113000538.html PASADENA, Calif., April 18, 2023--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 2, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter ended March 31, 2023.
von Breeze:MS BUYSIDE ADDED 203K SHARES LAST Q. They are not being cautious. They are lying. Follow the money. Pfizer spent $250M upfront for the Ionis version of ANG3, much earlier in its development than ARO-ANG3 is now. And it didn't work. ARO-ANG3 works. It is worth WAY more than that. Not hard to figure out. https://discord.com/channels/855125100146589706/857399412463763457
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics Jun 1, 2023
1 New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95%
2 Adipose Delivery Platform Achieved Single Dose Target Gene Silencing of Greater than 90% with Six Months of Duration in Non-human Primates
3 Improved Hepatic Dimer Platform Achieves Equivalent or Better Knockdown of Two Target Genes with Longer Duration than Monomer Mixture in Non-human Primates
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target of $90.00. The company’s shares closed yesterday at $35.00. https://markets.businessinsider.com/news/stocks/...ls-arwr-1032372406
Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences Jun 6, 2023 at 7:30 AM EDT PDF Version
PASADENA, Calif.--(BUSINESS WIRE)--Jun. 6, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
Jefferies Global Healthcare Conference – June 8, 2023 Type: Fireside chat presentation
Goldman Sachs 44th Annual Global Healthcare Conference – June 12, 2023 Type: Fireside chat presentation
European Association for the Study of the Liver (EASL) Congress 2023 – June 24, 2023 Type: Oral presentation Title: Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study Webcast links and presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. https://ir.arrowheadpharma.com/news-releases/...te-upcoming-june-2023
noch ein neues Labor? https://www.youtube.com/watch?v=Fs8c4yB-Vug Check out the progress on this 150,000+ square-foot research & development facility. This ongoing development is the future site of a 55-acre technology and life science campus in Scripps Ranch
Thread abonnieren
